In a routine screening of our small-molecule compound collection we recently identified 4-arylazo-3,5-diamino-1H-pyrazoles as a novel group of ATP antagonists with moderate potency against CDK2-cyclin E. A preliminary SAR study based on 35 analogues suggests ways in which the pharmacophore could be further optimized, for example, via substitutions in the 4-aryl ring. Enzyme kinetics studies with the lead compound and X-ray crystallography of an inhibitor-CDK2 complex demonstrated that its mode of inhibition is competitive. Functional kinase assays confirmed the selectivity toward CDKs, with a preference for CDK9-cyclin T1. The most potent inhibitor, 4-[(3,5-diamino-1H-pyrazol-4-yl)diazenyl]phenol 31b (CAN508), reduced the frequency of S-phase cells of the cancer cell line HT-29 in antiproliferation assays. Further observed cellular effects included decreased phosphorylation of the retinoblastoma protein and the C-terminal domain of RNA polymerase II, inhibition of mRNA synthesis, and induction of the tumor suppressor protein p53, all of which are consistent with inhibition of CDK9.

Laboratory of Growth Regulators Faculty of Science Palacký University and Institute of Experimental Botany Slechtitelů 11 783 71 Olomouc Czech Republic

000      

00000naa 2200000 a 4500

001      

bmc07524050

003      

CZ-PrNML

005      

20111210140706.0

008      

090528s2006 xxu e eng||

009      

AR

040    __

$a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2

041    0_

$a eng

044    __

$a xxu

100    1_

$a Kryštof, Vladimír, $d 1973- $7 xx0097406

245    10

$a 4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects / $c Krystof V, Cankar P, Frysová I, Slouka J, Kontopidis G, Dzubák P, Hajdúch M, Srovnal J, de Azevedo WF Jr, Orság M, Paprskárová M, Rolcík J, Látr A, Fischer PM, Strnad M.

314    __

$a Laboratory of Growth Regulators, Faculty of Science, Palacký University and Institute of Experimental Botany, Slechtitelů 11, 783 71 Olomouc, Czech Republic

520    9_

$a In a routine screening of our small-molecule compound collection we recently identified 4-arylazo-3,5-diamino-1H-pyrazoles as a novel group of ATP antagonists with moderate potency against CDK2-cyclin E. A preliminary SAR study based on 35 analogues suggests ways in which the pharmacophore could be further optimized, for example, via substitutions in the 4-aryl ring. Enzyme kinetics studies with the lead compound and X-ray crystallography of an inhibitor-CDK2 complex demonstrated that its mode of inhibition is competitive. Functional kinase assays confirmed the selectivity toward CDKs, with a preference for CDK9-cyclin T1. The most potent inhibitor, 4-[(3,5-diamino-1H-pyrazol-4-yl)diazenyl]phenol 31b (CAN508), reduced the frequency of S-phase cells of the cancer cell line HT-29 in antiproliferation assays. Further observed cellular effects included decreased phosphorylation of the retinoblastoma protein and the C-terminal domain of RNA polymerase II, inhibition of mRNA synthesis, and induction of the tumor suppressor protein p53, all of which are consistent with inhibition of CDK9.

650    _2

$a antimetabolity $x diagnostické užití $7 D000963

650    _2

$a azosloučeniny $x farmakologie $x chemická syntéza $7 D001391

650    _2

$a bromodeoxyuridin $x diagnostické užití $7 D001973

650    _2

$a buněčný cyklus $x účinky léků $7 D002453

650    _2

$a nádorové buněčné linie $7 D045744

650    _2

$a proliferace buněk $x účinky léků $7 D049109

650    _2

$a krystalografie rentgenová $7 D018360

650    _2

$a cyklin-dependentní kinasa 2 $x antagonisté a inhibitory $7 D051357

650    _2

$a cyklin-dependentní kinasy $x antagonisté a inhibitory $7 D018844

650    _2

$a inhibitory enzymů $x farmakologie $x chemická syntéza $7 D004791

650    _2

$a imunoblotting $7 D015151

650    _2

$a lidé $7 D006801

650    _2

$a molekulární modely $7 D008958

650    _2

$a pyrazoly $x farmakologie $x chemická syntéza $7 D011720

650    _2

$a RNA $x biosyntéza $x izolace a purifikace $7 D012313

650    _2

$a polymerázová řetězová reakce s reverzní transkripcí $7 D020133

650    _2

$a reverzní transkripce $x účinky léků $7 D048348

650    _2

$a vztahy mezi strukturou a aktivitou $7 D013329

650    _2

$a substrátová specifita $7 D013379

650    _2

$a financování organizované $7 D005381

700    1_

$a Cankař, Petr $7 xx0121905

700    1_

$a Fryšová, Iveta, $d 1974- $7 xx0018733

700    1_

$a Slouka, Jan, $d 1935- $7 jn20000402233

700    1_

$a Kontopidis, George

700    1_

$a Džubák, Petr $7 xx0080445

700    1_

$a Hajdúch, Marián, $d 1969- $7 xx0050218

700    1_

$a Srovnal, Josef $7 xx0091239

700    1_

$a de Azevedo, Walter F.

700    1_

$a Orság, Martin $7 xx0128389

700    1_

$a Paprskářová, Martina $7 xx0086519

700    1_

$a Rolčík, Jakub $7 xx0120212

700    1_

$a Látr, Aleš $7 xx0128707

700    1_

$a Fischer, Peter M.

700    1_

$a Strnad, Miroslav, $d 1958- $7 jn20010309068

773    0_

$w MED00010049 $t Journal of medicinal chemistry $g Roč. 49, č. 22 (2006), s. 6500-6509 $x 0022-2623

910    __

$a ABA008 $b x $y 9

990    __

$a 20090519102933 $b ABA008

991    __

$a 20091014152759 $b ABA008

999    __

$a ok $b bmc $g 659597 $s 515008

BAS    __

$a 3

BMC    __

$a 2006 $b 49 $c 22 $d 6500-6509 $i 0022-2623 $m Journal of medicinal chemistry $x MED00010049

LZP    __

$a 2009-B2/dkme